No Data
Hunan Er-kang Pharmaceutical (300267.SZ): It is expected to incur a loss of 0.29 billion yuan to 0.39 billion yuan in 2024.
On January 21, Gronghui reported that Hunan Er-kang Pharmaceutical (300267.SZ) announced that it expects a loss of 290 million to 390 million yuan in 2024, with a non-recurring loss of 296.45 million to 396.45 million yuan. 1. During the reporting period, changes occurred in the market supply and demand relationship for the company's pharmaceutical intermediates, composite excipients, and other products, leading to a decrease in sales volume and a significant drop in sales prices, which affected the company's profitability; additionally, investment losses in associated companies were proportionately recognized. 2. Based on the principle of prudence, the company will recognize impairment for assets showing signs of impairment within the consolidated financial statements, following the relevant regulations.
Erkang Pharmaceuticals: 2024 Annual Results Forecast
Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) Top Holders Are Insiders and They Are Likely Disappointed by the Recent 11% Drop
Hunan Er-Kang Pharmaceutical (SZSE:300267 Shareholders Incur Further Losses as Stock Declines 6.6% This Week, Taking Five-year Losses to 55%
Erkang Pharmaceuticals: Report for the third quarter of 2024
hunan er-kang pharmaceutical (300267.SZ): a net loss of 31.7675 million yuan in the third quarter.
On October 24, Gelonhui reported that Hunan Er-Kang Pharmaceutical (300267.SZ) achieved revenue of 0.233 billion yuan in the third quarter of 2024, a year-on-year decrease of 41.06%; net income attributable to shareholders of the listed company was -31.7675 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -34.3959 million yuan; basic earnings per share was -0.0154 yuan.
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
